30,044 results match your criteria Radiation Therapy Prostate Cancer

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study.

Ann Oncol 2021 Jun 12. Epub 2021 Jun 12.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

Background: The phase III CHAARTED trial established upfront androgen deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined.

Patients And Methods: Whole transcriptomic profiling was performed on primary prostate cancer (PC) tissue obtained from patients enrolled in CHAARTED prior to systemic therapy. Read More

View Article and Full-Text PDF

Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities.

Jpn J Clin Oncol 2021 Jun 14. Epub 2021 Jun 14.

Department of Radiation Oncology, Toyota Memorial Hospital, Toyota, Japan.

Objective: We aimed to report the 2-year results of stereotactic body radiation therapy for prostate cancer and identify the clinical and dosimetric factors that predict acute genitourinary toxicities.

Methods: We retrospectively reviewed the medical records of patients with non-metastatic prostate cancer treated at Toyota Memorial Hospital between 2017 and 2020. The patients were treated with stereotactic body radiation therapy with a total dose of 36. Read More

View Article and Full-Text PDF

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.

Cell Death Differ 2021 Jun 14. Epub 2021 Jun 14.

George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

Androgen-deprivation therapy (ADT) via targeting androgens/androgen receptor (AR) signals may suppress cell proliferation in both prostate cancer (PCa) and bladder cancer (BCa), yet its impact on the cell invasion of these two urological cancers remains unclear. Here we found targeting androgens/AR with either the recently developed antiandrogen Enzalutamide (Enz) or AR-shRNAs led to increase PCa cell invasion, yet decrease BCa cell invasion. Mechanistic dissection revealed that suppressing androgens/AR signals could result in differential alterations of the selective circular RNAs (circRNAs) as a result of differential endogenous AR transcription. Read More

View Article and Full-Text PDF

Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial).

Sci Rep 2021 06 14;11(1):12470. Epub 2021 Jun 14.

Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.

Lifestyle interventions involving exercise training offset the adverse effects of androgen deprivation therapy in men with prostate cancer. Yet provision of integrated exercise pathways in cancer care is sparse. This study assessed the feasibility and acceptability of an embedded supervised exercise training intervention into standard prostate cancer care in a single-arm, multicentre prospective cohort study. Read More

View Article and Full-Text PDF

Optimisation of user-selectable volumetric modulated arc therapy (VMAT) planning parameters: VMAT arcs for prostate and head-and-neck cancers.

J Pak Med Assoc 2021 Apr;71(4):1093-1099

Department of Mathematics, NAMAL INSTITUTE Mianwali, Pakistan.

Objective: To evaluate different VMAT planning techniques for a multi-leaf collimator (MLC)providing maximum aperture of 21 × 16 cm².

Methods: A VMAT planning study of nine prostate and nine head-and-neck cancer patients was carried out. The patients were previously treated with Intensity Modulated Radiotherapy (IMRT) technique during 2014-15, at radiation oncology SanBortolo Hospital, Vicenza, Italy. Read More

View Article and Full-Text PDF

Editorial: Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic Ratio in the Modern Radiation Therapy Era.

Front Oncol 2021 26;11:690649. Epub 2021 May 26.

Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

View Article and Full-Text PDF

Statistical Evaluation of Different Mathematical Models for Diffusion Weighted Imaging of Prostate Cancer Xenografts in Mice.

Front Oncol 2021 26;11:583921. Epub 2021 May 26.

Department of Radiology, University of Turku, Turku, Finland.

Purpose: To evaluate fitting quality and repeatability of four mathematical models for diffusion weighted imaging (DWI) during tumor progression in mouse xenograft model of prostate cancer.

Methods: Human prostate cancer cells (PC-3) were implanted subcutaneously in right hind limbs of 11 immunodeficient mice. Tumor growth was followed by weekly DWI examinations using a 7T MR scanner. Read More

View Article and Full-Text PDF

Rectal wall sparing effect of a rectal retractor in prostate intensity-modulated radiotherapy.

J Cancer Res Ther 2021 Apr-Jun;17(2):383-388

Department of Medical Physics, School of Medicine, Iran University of Medical Sciences; Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Purpose: The objective of the study was to evaluate the effectiveness of a rectal retractor (RR) designed to protect rectal tissue in intensity-modulated radiotherapy (IMRT) by pushing rectal wall (RW) away from the prostate.

Materials And Methods: Twelve patients with localized prostate cancer were enrolled into this study. Patients underwent two computed tomography (CT) scans without and with RR. Read More

View Article and Full-Text PDF

To evaluate volume changes on computerized tomography scan and magnetic resonance imaging-based delineation during radiotherapy treatment planning in prostate cancer.

J Cancer Res Ther 2021 Apr-Jun;17(2):379-382

Department of Radiation Oncology, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India.

Aim: The aim of the present study was to evaluate the impact of magnetic resonance imaging (MRI) on radiotherapy target volume changes in prostate cancer.

Materials And Methods: Ten patients with localized prostate cancer receiving radical radiotherapy were included in the study. Computerized tomography (CT) simulation was done with adequate immobilization, and pelvic MRI was also done at the same time. Read More

View Article and Full-Text PDF

Helical tomotherapy for prostate cancer radiation therapy: An audit of early toxicity and quality of life.

J Cancer Res Ther 2021 Apr-Jun;17(2):366-371

Department of Amrita School of Medicine, AIMS, Amrita Vishwa Vidyapeetham, Kochi, India.

Background: Radiation plays a major role in the management of localized prostate cancer (CaP). There are limited studies reporting the quality of life (QOL) and toxicity with CaP tomotherapy.

Materials And Methods: This is a single-institutional prospective observational study evaluating the acute toxicity and QOL of patients with CaP receiving tomotherapy from May 2018 to October 2019. Read More

View Article and Full-Text PDF

Ultrasound-guided transrectal implantation of fiducial markers for image-guided radiotherapy of prostate cancer without local anesthesia: Patient-reported gastrointestinal-genitourinary system complications and pain.

Cenk Ahmet Sen

J Cancer Res Ther 2021 Apr-Jun;17(2):353-357

Department of Radiation Oncology, Izmir Medical Park Hospital, Izmir, Turkey.

Purpose: The present study evaluates procedure-associated pain and side effects in the gastrointestinal-genitourinary system in patients with early-stage prostate cancer who were treated with image-guided radiotherapy (IGRT), accompanied by an ultrasound-guided transrectal implantation of fiducial markers, without local anesthesia.

Materials And Methods: A total of 46 patients who referred to our clinics between 2012 and 2017 with a diagnosis of early-stage prostate cancer were included in the study. Before undergoing radiotherapy, all patients were implanted with three intraprostatic fiducial markers through the ultrasound-guided transrectal approach without local anesthesia. Read More

View Article and Full-Text PDF

Effectiveness of rectal displacement devices during prostate external-beam radiation therapy: A review.

J Cancer Res Ther 2021 Apr-Jun;17(2):303-310

Department of Medical Physics, School of Medicine, Iran University of Medical Sciences; Department of Medical Physics, Roshana Cancer Institute, Tehran, Iran.

Dose-escalated prostate radiotherapy (RT) can improve treatment outcomes, but rectal toxicity is the main limiting factor for introducing dose-escalated RT. Pushing rectal wall away from the prostate reduces the volume of the rectum in high-dose region, which can decrease both short- and long-term rectal toxicities after RT. This review focuses on the literature using different rectal displacement devices such as endorectal balloons, tissue spacers, rectal retractor, and ProSpare during prostate External beam radiotherapy, with regard to dosimetric effects, clinical benefits, prostate motion, and postoperative RT setting. Read More

View Article and Full-Text PDF

Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.

Support Care Cancer 2021 Jun 13. Epub 2021 Jun 13.

Gastroenterology and Digestive Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France.

Purpose: Naloxegol, an oral once-daily peripherally acting mu-opioid receptor antagonist, is indicated for the treatment of opioid-induced constipation (OIC) with inadequate response to laxative(s), in cancer and non-cancer patients. This study mainly aimed to assess in real-life conditions the efficacy and safety of naloxegol in cancer pain patients and the evolution of their quality of life.

Methods: A non-interventional, 4-week follow-up study was conducted in 24 French oncology and pain centers between 2018 and 2019. Read More

View Article and Full-Text PDF

Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison.

Radiat Oncol 2021 Jun 12;16(1):107. Epub 2021 Jun 12.

Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyoku, Tokyo, 113-8655, Japan.

Background: The efficacy of a hydrogel spacer in stereotactic body radiotherapy (SBRT) has not been clarified. We evaluated the safety and efficacy of SBRT in combination with a hydrogel spacer for prostate cancer.

Methods: This is a prospective single-center, single-arm phase II study. Read More

View Article and Full-Text PDF

Low conflict and high satisfaction: Decisional outcomes after attending a combined clinic to choose between robotic prostatectomy and radiotherapy for prostate cancer.

Urol Oncol 2021 Jun 8. Epub 2021 Jun 8.

Centre for Oncology Education and Research Translation (CONCERT), Ingham Institute for Applied Medical Research & University of New South Wales, Liverpool, NSW; South Western Sydney Clinical School, University of New South Wales, Liverpool , NSW.

Background: Decisional conflict and post-treatment decisional regret have been documented in men with localised prostate cancer (LPC). However, there is limited evidence regarding decisional outcomes associated with the choice between robotic-assisted radical prostatectomy (RARP) and radiotherapy, when both treatment options are available in the public health system. There is increasing support for multidisciplinary approaches to guide men with LPC in their decision-making process. Read More

View Article and Full-Text PDF

Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.

Med Oncol 2021 Jun 11;38(7):81. Epub 2021 Jun 11.

Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Centre, Baskent University Faculty of Medicine, 01120, Adana, Turkey.

View Article and Full-Text PDF

Estimating heterogeneous survival treatment effect in observational data using machine learning.

Stat Med 2021 Jun 10. Epub 2021 Jun 10.

Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA.

Methods for estimating heterogeneous treatment effect in observational data have largely focused on continuous or binary outcomes, and have been relatively less vetted with survival outcomes. Using flexible machine learning methods in the counterfactual framework is a promising approach to address challenges due to complex individual characteristics, to which treatments need to be tailored. To evaluate the operating characteristics of recent survival machine learning methods for the estimation of treatment effect heterogeneity and inform better practice, we carry out a comprehensive simulation study presenting a wide range of settings describing confounded heterogeneous survival treatment effects and varying degrees of covariate overlap. Read More

View Article and Full-Text PDF

Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer.

Clin Transl Radiat Oncol 2021 Jul 21;29:40-46. Epub 2021 May 21.

Department of Radiation Oncology, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands.

Background And Purpose: For irradiation of localized prostate-cancer, moderately-hypofractionated regimens with a variety of dose per fraction are used. We adopted a regimen of 70 Gy in 28 fractions of 2.5 Gy, using state of the art radiotherapy (RT) and closely monitored the efficacy, toxicity and health-related quality of life (HRQoL) in a large cohort, using patient-reported outcomes. Read More

View Article and Full-Text PDF

Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres.

Sci Rep 2021 Jun 10;11(1):12323. Epub 2021 Jun 10.

Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.

To assess adherence to standard clinical practice for the diagnosis and treatment of patients undergoing prostate cancer (PCa) radiotherapy in four European countries using clinical audits as part of the international IROCA project. Multi-institutional, retrospective cohort study of 240 randomly-selected patients treated for PCa (n = 40/centre) in the year 2015 at six European hospitals. Clinical indicators applicable to general and PCa-specific radiotherapy processes were evaluated. Read More

View Article and Full-Text PDF

Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.

Clin Cancer Res 2021 Jun 10. Epub 2021 Jun 10.

Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco.

Purpose: In the placebo-controlled SPARTAN study, apalutamide added to androgen-deprivation therapy (ADT) improved metastasis-free survival, second progression-free survival, and overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Mechanisms of resistance to apalutamide in nmCRPC require evaluation.

Experimental Design: In a subset of patients from SPARTAN, aberrations were assessed at baseline and end of study treatment (EOST) using targeted next-generation sequencing or quantitative reverse transcription PCR. Read More

View Article and Full-Text PDF

A deep learning-based framework for segmenting invisible clinical target volumes with estimated uncertainties for post-operative prostate cancer radiotherapy.

Med Image Anal 2021 May 17;72:102101. Epub 2021 May 17.

Medical Artificial Intelligence and Automation Laboratory and Department of Radiation Oncology,University of Texas Southwestern Medical Center, Dallas, Texas, United States. Electronic address:

In post-operative radiotherapy for prostate cancer, precisely contouring the clinical target volume (CTV) to be irradiated is challenging, because the cancerous prostate gland has been surgically removed, so the CTV encompasses the microscopic spread of tumor cells, which cannot be visualized in clinical images like computed tomography or magnetic resonance imaging. In current clinical practice, physicians' segment CTVs manually based on their relationship with nearby organs and other clinical information, but this allows large inter-physician variability. Automating post-operative prostate CTV segmentation with traditional image segmentation methods has yielded suboptimal results. Read More

View Article and Full-Text PDF

Effect of 1α,25-Dihydroxyvitamin D3 on the Radiation Response in Prostate Cancer: Association With IL-6 Signaling.

Front Oncol 2021 24;11:619365. Epub 2021 May 24.

College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Radiotherapy (RT) is the main treatment modality for prostate cancer (PCa). This study investigated the role of IL-6 in biological sequelae following irradiation and highlighted the effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on the radiation response of PCa and its relationship with IL-6 signaling. Human and murine PCa cell lines were used to examine the response to irradiation and . Read More

View Article and Full-Text PDF

Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function.

Prostate Cancer Prostatic Dis 2021 Jun 9. Epub 2021 Jun 9.

Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: Sexual dysfunction, including erectile dysfunction and loss of libido, are common among men undergoing treatment for localized prostate cancer. Both local treatments and systemic androgen deprivation therapy may contribute to these outcomes and are differentially indicated based on disease characteristics. We sought to compare sexual function through 5 years after radiation treatment with and without androgen deprivation therapy in men with good baseline sexual function to better understand long-term effects in this understudied subset of patients. Read More

View Article and Full-Text PDF

Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.

Prostate Cancer Prostatic Dis 2021 Jun 9. Epub 2021 Jun 9.

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.

Background: Expectant management (EM) has been widely recommended for men with low-risk prostate cancers (PCa). We evaluated trends in EM and the sociodemographic and clinical factors associated with EM, initiating a National Comprehensive Cancer Network guideline-concordant active surveillance (AS) monitoring protocol, and switching from EM to active treatment (AT).

Methods: We used the SEER-Medicare database to identify men ages 66+ diagnosed with a low-risk PCa (PSA < 10 ng/mL, Gleason ≤ 6, stage ≤ T2a) in 2010-2013 with ≥1 year of follow-up. Read More

View Article and Full-Text PDF

[A Case of Ureteral Metastasis from Prostate Cancer].

Hinyokika Kiyo 2021 Apr;67(4):171-176

The Department of Urology, Kobe City Nishi-Kobe Medical Center.

Ureteral metastasis from prostate cancer is rare. The present case report describes an 83-year-old patient with distant metastasis of prostate cancer to the right ureter that caused hydronephrosis. Upon initial examination at our hospital, he presented with a high prostate-specific antigen (PSA) level of 10. Read More

View Article and Full-Text PDF

A hierarchical deep reinforcement learning framework for intelligent automatic treatment planning of prostate cancer intensity modulated radiation therapy.

Phys Med Biol 2021 Jun 9. Epub 2021 Jun 9.

Department of Radiation Oncology, UT Southwestern Medical Center, 6363 Forest Park Rd. BL10.202G, MC9315, Dallas, Texas, 75390-9315, UNITED STATES.

Although the potential of virtual treatment planner network (HieVTPN) in automating radiotherapy (RT) treatment planning has been demonstrated, its poor scalability caused by an almost linear growth of network size with the number of treatment planning parameters (TPPs) is a bottleneck, preventing its application in complicate, but clinically relevant planning problems. Motivated by the decision-making process of a human planner, this study proposes a hierarchical framework. The proposed hierarchical VTPN (HieVTPN) consists of Structure-Net, Parameter-Net, and Action-Net. Read More

View Article and Full-Text PDF

Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.

Cancer Sci 2021 Jun 9. Epub 2021 Jun 9.

QST Hospital, Quantum Medical Science Directorate, National Institutes for Quantum and Radiological Science and Technology (formerly, the hospital of National Institute of Radiological Science), Chiba, Japan.

There are no clinical reports of long-term follow-up after carbon-ion radiotherapy (CIRT) using a dose of 51.6 Gy (RBE) in 12 fractions for localized prostate cancer, or of a comparison of clinical outcomes between passive and scanning beam irradiation. A total of 256 patients with localized prostate cancer who received CIRT at a dose of 51. Read More

View Article and Full-Text PDF

Robot-assisted radical prostatectomy in the Middle East: A report on the perioperative outcomes from a tertiary care centre in Lebanon.

Arab J Urol 2020 Aug 26;19(2):152-158. Epub 2020 Aug 26.

Division of Urology, Department of Surgery, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.

Objective: To report on the surgical, oncological and early functional outcomes of robot-assisted radical prostatectomy (RARP) at our tertiary care centre, as there is a scarcity of reports on outcomes of robotic surgery from the Middle East.

Patients And Methods: We reviewed the electronic health records for patients undergoing RARP between 2013 and 2019 at the American University of Beirut Medical Center. We collected patients' demographics and preoperative oncological factors including prostate-specific antigen (PSA), clinical oncological stage, and World Health Organization (WHO) grade. Read More

View Article and Full-Text PDF

Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial.

Ther Adv Endocrinol Metab 2021 5;12:20420188211012118. Epub 2021 May 5.

Department of Medicine (Austin Health), The University of Melbourne, VIC, Australia.

Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resulting in increased insulin resistance. Read More

View Article and Full-Text PDF

Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization.

Cancer Manag Res 2021 31;13:4291-4298. Epub 2021 May 31.

Department of Urology, Jagiellonian University Medical College, Krakow, Poland.

Purpose: Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method. Read More

View Article and Full-Text PDF